Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel

Japanese Journal of Clinical Oncology 2026

View at publisher
Authors: Taizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, Taisuke Jo, Hirofumi Morinaka, Wataru Fukuokaya, Atsuhiko Yoshizawa, Masanobu Saruta, Tsuyoshi Morita, Saizo Fujimoto, Yutaka Yamamoto, Moritoshi Sakamoto
+16 more Kazuki Nishimura, Ryoichi Maenosono, TAKUYA TSUJINO, Kyosuke Nishio, Yuki Yoshikawa, Atsushi Ichihashi, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuzuki, Kiyoshi Takahara, TERUO INAMOTO, Kazutoshi Fujita, Haruhito Azuma, Takahiro Kimura, Kazumasa Komura
DOI: 10.1093/jjco/hyag011
Cited by: 1
References: 29

Abstract

BACKGROUND: Triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel (DOC) has emerged as an intensified treatment option for metastatic castration-sensitive prostate cancer (mCSPC). This study evaluated real-world prostate specific antigen (PSA) responses and adverse events (AEs) associated with triplet therapy, with a focus on age-specific differences. METHODS: We performed a retrospective cohort study across six academic institutions in Japan between February 2023 and February 2025. A total of 137 patients with mCSPC who received triplet therapy were analyzed. PSA responses and AEs were assessed, including subgroup analyses by age (

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Japanese Journal of Clinical Oncology
Publisher
Oxford University Press (OUP)
Volume
56
Issue
5
Pages
628–635
Publication date
13 January 2026
Language
EN